SGResearchers from the National University of Singapore's Yong Loo Lin School of Medicine have discovered a drug called Supinoxin (RX-5902) that targets a 'master switch' gene called DP103, which drives tumor growth in triple-negative breast cancer. This type of cancer is particularly aggressive and affects younger women, as it lacks receptors commonly targeted by existing cancer drugs. The study found that the drug significantly reduces cancer stem cell viability and tumor growth in laboratory models, with minimal impact on healthy cells. The research was published in the journal Cell Death And Disease and highlights potential for personalized treatment strategies based on DP103 as a biomarker.
Bias read (Center): The article discusses scientific research related to medical advancements in treating a specific type of cancer. It presents factual information about the discovery, methodology, and results of the study without apparent ideological framing or bias. There is no mention of political figures, policies
